Biomedical Systems to collaborate with Mass. General Hospital

Friday, August 17, 2012 03:19 PM

The imaging division of Biomedical Systems, a global provider of centralized diagnostic services, has formed a collaboration with Massachusetts General Hospital (MGH) to evaluate the efficacy of new drugs and devices.

Biomedical Systems’ digital medical imaging technologies support clinical trials by capturing the body’s reaction to a new drug or device to determine its effectiveness. The images are then read by a radiologist, which historically Biomedical hand-selected based on the clinical trial criteria and expertise in the anatomical region or disease pathology.

MGH will provide Biomedical Systems with a dedicated reading room to expedite image reviews by hospital radiologists who review information from more than 200 clinical trials. The agreement allows Biomedical Systems and MGH’s radiology teams to meet aggressive deadlines while safeguarding the clinical trials’ accuracy.

“Our goal is to ensure that the information we provide when reviewing images is not only timely, but most importantly, accurate,” said Amy Corbosiero, manager of drug trials operations in MGH Imaging. “It is especially important in clinical trials that variability is low. It is in all of our best interests to make sure that the most accurate clinical data is factored into studies that determine which drugs and devices will one day be available to the patients we serve.”

Biomedical’s collaboration with MGH is not exclusive, and allows the company to work with specialty radiologists around the world as dictated by the clinical trial.

“Our job is to help drug and medical device developers determine if their health innovation meets its intended objectives,” said Jeffrey Bowden, president, imaging services, Biomedical Systems. “It’s critical for our clients to know they have access to superior imaging technology and the industry’s most revered radiologists so they can trust the data and meet their critical timelines. Our collaboration with MGH ensures our images will be read by expert radiologist professionals at any time—evenings or weekends when needed.  Still, we have the freedom to partner with other specialty radiologists when warranted and remain dedicated to working and innovating with relevant medical industries.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs